Skip to main content
BICYCLE THERAPEUTICS PLC logo

BICYCLE THERAPEUTICS PLC — Investor Relations & Filings

Ticker · BCYC ISIN · US0887861088 LEI · 213800XKUI6R7GKC3E43 US Manufacturing
Filings indexed 598 across all filing types
Latest filing 2023-01-23 Board/Management Inform…
Country GB United Kingdom
Listing US BCYC

About BICYCLE THERAPEUTICS PLC

https://www.bicycletherapeutics.com/

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines known as Bicycle® molecules. These are fully synthetic bicyclic peptides engineered to combine the targeting specificity and pharmacological properties of large molecule biologics with the rapid and deep tissue penetration of small molecules. The company's proprietary platform creates precision-guided therapeutics to address diseases underserved by existing treatments. The primary focus of its development pipeline is in oncology, with a portfolio of candidates designed to target solid tumors. Beyond oncology, Bicycle Therapeutics leverages its technology through collaborations to explore applications in other therapeutic areas, including anti-infectives, cardiovascular diseases, and central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 17, 2023, reporting amendments to employment agreements of key executives including the CEO, CFO, and CTO. The content focuses on changes in compensatory arrangements related to termination events and change of control. There is no financial data or comprehensive report content; rather, it is an announcement of management changes in employment terms. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management or board members. The document length is under 5,000 characters and is a standalone announcement, not a full report or certification. Therefore, the appropriate classification is MANG with high confidence.
2023-01-23 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-06 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.